ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Operating Income history
Currency unavailable · from the income statement
No Operating Income data reported for this period type.
Operating Income vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -€46.45M EUR | -39.8% | — | 345.5% | |
| LTM Mar 2026 | -$53.94M USD | -43.9% | — | — | |
| FY2025 | -$76.81M USD | — | — | 412.6% | |
| LTM Mar 2026 | -$86.59M USD | — | — | 9396.6% | |
| LTM Mar 2026 | -$89.22M USD | -8.7% | — | 196.7% | |
| LTM Mar 2026 | -$105.19M USD | +33.9% | — | 131.9% | |
| LTM Mar 2026 | -$185.25M USD | -584.4% | — | 577.5% | |
| LTM Mar 2026 | -$196.88M USD | -56.6% | — | 274.2% | |
| LTM Mar 2026 | -$206.61M USD | -0.0% | — | 5121.8% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -39.8% | — | 379.0% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.